Skip to content
Cultural Foundation
Author:
Aravax
Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026
October 5, 2026
Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy
August 3, 2026
Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby
April 8, 2026